These cells are implanted in a durable and
retrievable encapsulation device called the Encaptra ® drug delivery system.
ViaCyte's product candidates are based on the derivation of pancreatic progenitor cells, which are then implanted in a durable and
retrievable encapsulation device.
The VC - 01 combination product is based on the production of pancreatic progenitor cells (PEC - 01 ™ cells), which are implanted in a durable and
retrievable encapsulation device, known as the Encaptra ® drug delivery system.
These cells are implanted using a durable and
retrievable encapsulation device.